ArticleBiofabrication2022
Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line.
Article in Biofabrication, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Recapitulating patient-to-patient colorectal cancer tumor heterogeneity using patient-derived xenograft cells in an engineered tissue model.Acta biomaterialia · 2026Article
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- Recapitulating Patient-to-Patient Colorectal Cancer Tumor Heterogeneity Using Patient-Derived Xenograft Cells in an Engineered Tissue Model.bioRxiv : the preprint server for biology · 2025Article
- Establishment of a tissue-engineered colon cancer model for comparative analysis of cancer cell lines.Journal of biomedical materials research. Part A · 2024Article
- A preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment.Biomaterials research · 2023Article
- Review
- Patient-derived xenograft models in cancer therapy: technologies and applications.Signal transduction and targeted therapy · 2023Review
- Application of a 3D hydrogel-based model to replace use of animals for passaging patient-derived xenografts.In vitro models · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The development of physiologically relevant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.